CN104523774A - Sarcandra glabra chewable tablets and preparation method thereof - Google Patents
Sarcandra glabra chewable tablets and preparation method thereof Download PDFInfo
- Publication number
- CN104523774A CN104523774A CN201410763905.4A CN201410763905A CN104523774A CN 104523774 A CN104523774 A CN 104523774A CN 201410763905 A CN201410763905 A CN 201410763905A CN 104523774 A CN104523774 A CN 104523774A
- Authority
- CN
- China
- Prior art keywords
- herba sarcandrae
- parts
- extract
- chewable tablet
- filler
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to sarcandra glabra chewable tablets and a preparation method thereof. The sarcandra glabra chewable tablets are prepared from the following components in parts by weight: 3000-3200 parts of sarcandra glabra, 210-230 parts of filler, 5-15 parts of an adhesive, 4-8 parts of a corrigent and 1-5 parts of a lubricant, wherein the filler is selected from one or more of mannitol, lactose or L-arabinose, the adhesive is polyvinylpyrrolidone and the lubricant is superfine silica powder. The invention further provides the preparation method of the tablets. The sarcandra glabra chewable tablets can be used for solving the problem that existing sarcandra glabra tablets are heavy and large and are hard to swallow, improving the taste of the medicine, and meanwhile solving the problem that the efficacy of sarcandra glabra cannot be given to play extremely as existing extraction and preparation methods and processes are not scientific.
Description
Technical field
The present invention relates to a kind of chewable tablet and preparation method thereof, be specifically related to a kind of Herba Sarcandrae chewable tablet and preparation method thereof, belong to medical art,
Background technology
Herba Sarcandrae, another name Herba Pileae Scriptae, Herba Pileae Scriptae, Herba Pileae Scriptae, synthetism lotus, anti-swollen No. I etc., be the dry Herb of Chloranthaceae plant plait Corallium Japonicum Kishinouye Sarcandra glabra (Thunb.) Nakai.Leaf is containing coumarone, lactone, flavone, phenols, cyanogen glycoside, volatile oil and Bulbus Allii tannic acid; Fruit is containing pelargonidin Fructus rhamni (Rhamnus davurica Pall.) glucose.Main component is volatile oil (having linalyl acetate etc. in oil), succinic acid, Fumaric acid, coumarone, flavonoid glycoside, lactone, tannic acid etc.
Herba Sarcandrae has dispelling wind and removing obstruction in the collateral, blood circulation promoting and blood stasis dispelling function, and has antibacterial, antiinflammation, has heat-clearing and toxic substances removing, effect of dispersing swelling and dissipating binds, belongs to hyperactivity of toxic heat patient for pneumonia, appendicitis, cellulitis, and can be used for assistant treating cancer.
Herba Sarcandrae has following pharmacological action:
Antibacterial and anti-inflammation functions, Herba Sarcandrae has broad-spectrum antibacterial action, is wherein extremely quick to staphylococcus aureus, dysentery bacterium I, to golden Portugal persister, Boydii dysentery bacterium C-2 type, Bacillus typhi H
901, paratyphoid fever A type is Gao Min, also has certain effect to bacterium flexneri III type, escherichia coli, bacillus pyocyaneus.Fumaric acid quick paramount quick inhibitory action in having first streptococcus, micrococcus catarrhalis, streptococcus, hemophilus influenza, Diplococcus pneumoniae in Herba Sarcandrae.Herba Sarcandrae is to rat paw inflammation caused by the not Mus auricle inflammation caused by Oleum Tiglii, carrageenin and mice cotton balls internal bud is swollen significant inhibitory action.In addition, the growth of stomachache caused by acetic acid and anti-bacteria can also obviously be alleviated.
Antitumaous effect, Herba Sarcandrae extract and total volatile oil have obvious anti-S
180and W
256the effect of tumor strain, wherein mouse peritoneal injection crude extract 0.25g/kg, to S
180suppression ratio be 42% ~ 49.4% (P < 0.001), to rat W
256suppression ratio be 39.0% (P < 0.01), lumbar injection volatile oil component linalyl acetate 1mg/kg, to S
180suppression ratio be 45.3% (P < 0.001).Herba Sarcandrae total flavones has inhibitory action to ribonucleic acid in ehrlich ascites cell (RNA) and DNA (deoxyribonucleic acid) (DNA) content.
Herba Sarcandrae clinically with other drug matching, for antitumor, antiinflammatory, treatment acute upper respiratory tract infection, treatment thrombocytopenia, treatment digestive system disease, treatment oral disease, treatment psoriasis etc., all obtain satisfied curative effect, but because the traditional extraction process level of understanding limit, not yet scientific research is goed deep into extraction process, its curative effect does not reach optimization, and therefore patent medicine effect is general separately, in Clinical practice, do not have advantage.
Domestic existing Herba Sarcandrae chewable tablet has ZHONGJIEFENG ZHUSHEYE, Zhongjiefeng Capsules and ZHONGJIEFENG PIAN.Herba Sarcandrae blade of having gone on the market weighs 500 ~ 750mg, and flap-type is unfavorable for greatly swallowing, and especially brings larger misery for laryngopharynx swelling and pain patient consumes.
Summary of the invention
The present invention improves on the basis of ZHONGJIEFENG PIAN, object is the problem solving the great dysphagia of current Herba Sarcandrae blade, improve medicine mouthfeel, change existing extraction and formulation method and technique simultaneously and owe science, at utmost can not play the problem of Herba Sarcandrae drug effect, there is provided that a kind of taking convenience, mouthfeel are good, toxic and side effects is little, drug effect improved, onset rapidly, be conducive to the Herba Sarcandrae chewable tablet that curative effect of medication plays, and provide its preparation method.
For solving the problem, technical scheme of the present invention is:
A kind of Herba Sarcandrae chewable tablet, it is prepared from by the composition of following weight portion: Herba Sarcandrae 3000 ~ 3200 parts, filler 210 ~ 230 parts, binding agent 5 ~ 15 parts, correctives 4 ~ 8 parts, lubricant 1 ~ 5 part, wherein, described filler be selected from mannitol, lactose or L-arabinose one or more, described binding agent is polyvinylpyrrolidone, and described lubricant is micropowder silica gel.
Preferably, Herba Sarcandrae chewable tablet of the present invention, it is prepared from by the composition of following weight portion: Herba Sarcandrae 3125 parts, filler 220 parts, binding agent 10 parts, correctives 6 parts, lubricant 3 parts.
Further preferably, Herba Sarcandrae chewable tablet of the present invention, wherein, described filler is mannitol: lactose: L-arabinose weight ratio is the mixture of 9:7:6.
Preferably, Herba Sarcandrae chewable tablet of the present invention, wherein, described correctives is flavoring orange essence.
Preferably, Herba Sarcandrae chewable tablet of the present invention, it is prepared from according to following preparation method:
Step one: get Herba Sarcandrae Herb, chopping, extracts, concentrated, and it is for subsequent use to dry, pulverize into Herba Sarcandrae extract;
Step 2: the Herba Sarcandrae extract of step one gained fully mixes with filler, correctives, the aqueous povidone solution with 5 ~ 10%, as binder solution soft material, crosses 20 mesh sieve granules, 50 ~ 60 DEG C of dryings 1 ~ 2 hour, and 16 order granulate are for subsequent use;
Step 3: the dried particles of step 2 gained adds mix lubricant evenly, and tabletting, to obtain final product.
Preferably, Herba Sarcandrae chewable tablet of the present invention, wherein, in described preparation method, the concrete operation method of step one is: Herba Sarcandrae coarse crushing, add 10,8,8 times amount soak by water three times, 4 ~ 5 hours first times, be respectively 1 ~ 2 hour for the second time, for the third time, decocting liquid filters, filtrate merges, and is condensed into relative density 1.1 ~ 1.15g/cm
3thick paste, drying under reduced pressure becomes dry extract, pulverizes, and wherein, collect volatile oil in first time decoction process, the atomization of gained volatile oil evenly sprays in the dry extract after pulverizing, obtains Herba Sarcandrae extract.
The present invention also provides the preparation method of described Herba Sarcandrae chewable tablet, and it comprises the steps:
Step one: get Herba Sarcandrae Herb, chopping, extracts, concentrated, and it is for subsequent use to dry, pulverize into Herba Sarcandrae extract;
Step 2: the Herba Sarcandrae extract of step one gained fully mixes with filler and correctives, the aqueous povidone solution with 5%, as binder solution soft material, crosses 20 mesh sieve granules, 50 ~ 60 DEG C of dryings 1 ~ 2 hour, and 16 mesh sieve granulate are for subsequent use;
Step 3: the dried particles of step 2 gained adds mix lubricant evenly, tabletting.
Further, the preparation method of Herba Sarcandrae chewable tablet of the present invention, wherein, the concrete operations of described step one are: Herba Sarcandrae coarse crushing, add 10,8,8 times amount soak by water three times, 4 ~ 5 hours first times, for the second time, third time is respectively 1 ~ 2 hour, decocting liquid filters, and filtrate merges, and is condensed into relative density 1.1 ~ 1.15g/cm
3thick paste, drying under reduced pressure becomes dry extract, pulverizes, and wherein, collect volatile oil in first time decoction process, the atomization of gained volatile oil evenly sprays in the dry extract after pulverizing, obtains Herba Sarcandrae extract.
Excellent results of the present invention is:
1, Herba Sarcandrae chewable tablet of the present invention, the basis of existing ZHONGJIEFENG PIAN is carried out transform and obtain, it improves on Herba Sarcandrae traditional extraction technique, and the first, by investigating kind and the addition of Extraction solvent, determine optimum extraction scheme, the second, in water extraction process, collect volatile oil, ensure that the abundant reservation of volatility water insoluble ingredients, breach the restriction of traditional handicraft, be surprised to find that obtained chewable tablet drug effect significantly improves compared with conventional tablet.
2, the present invention is by investigating the investigation of filler kind and quantity, the preferably kind of filler and additional proportion, final preferably mannitol, lactose and L-arabinose, wherein, mannitol can be chewable tablet and brings refrigerant mouthfeel, lactose compressibility is good, L-arabinose tool sweet taste, in addition, disintegrating agent is investigated, for chewable tablet, the selection of disintegrating agent is most important, if select unreasonablely may cause medicine not collapsing in mouth, affect mouthfeel and drug effect performance, inventor is surprised to find that in the research of Herba Sarcandrae chewable tablet, L-arabinose can produce the effect of disintegrating agent sample in Herba Sarcandrae chewable tablet, substitute other disintegrating agents and create excellent effect, compared with other disintegrating agents, better disintegration can be produced, through repetition test, inventor is by mannitol, lactose and L-arabinose three are according to after 9:7:6 mixing, gained tablet smooth in appearance, mouthfeel is good, disintegrate is effective, tabletting yield is high.In addition, the present invention has investigated the effect of different binding agent, finally determines that the polyvinylpyrrolidone of 5 ~ 10% is binding agent granule, and disintegrate, the dissolution of gained tablet are desirable.The present invention adds correctives to improve mouthfeel, preferred flavoring orange essence, increases convenience and patient's compliance, is especially applicable to laryngopharynx swelling and pain patient and takes.
3, Herba Sarcandrae chewable tablet of the present invention, is shown by the pharmacodynamic evaluation test of rat ear inflammatory model: Herba Sarcandrae chewable tablet antiphlogistic effects of the present invention is better than the tablet that goes on the market, and result has significant difference.
4, Herba Sarcandrae chewable tablet of the present invention, is shown by acute toxicity and mutagenicity research: Herba Sarcandrae its mouse oral LD
50measure and belong to nontoxic scope, mouse inbred strain, mouse marrow cell micro nuclear test, Salmonella reversion test are feminine gender, do not find mutagenicity.Herba Sarcandrae chewable tablet of the present invention is to large and small Mus acute oral median lethal dose(LD 50) (LD
50), bisexuality is all greater than 10g/kgB.W., and true border is nontoxic.
Detailed description of the invention
The present invention is specifically implemented by following examples, and following examples may be used for explaining the present invention but not as the restriction of scope.
Embodiment 1
Get the raw materials ready according to following prescription:
Herba Sarcandrae 3125g, mannitol 90g, lactose 70g, L-arabinose 60g, polyvinylpyrrolidone 10g, flavoring orange essence 6g, micropowder silica gel 3g.
Method for making:
Step one: get Herba Sarcandrae Herb, chopping, extracts, concentrated, and it is for subsequent use to dry, pulverize into Herba Sarcandrae extract; Wherein, the leaching process of Herba Sarcandrae is: Herba Sarcandrae coarse crushing, adds 10,8,8 times amount soak by water three times, 4 hours first times, second and third difference 1.5 hours, and decocting liquid filters, and filtrate merges, and is condensed into relative density 1.1 ~ 1.15g/cm
3thick paste, drying under reduced pressure becomes dry extract, pulverizes, and wherein, collect volatile oil in first time decoction process, the atomization of gained volatile oil evenly sprays in the dry extract after pulverizing, obtains Herba Sarcandrae extract;
Step 2: the Herba Sarcandrae extract of step one gained fully mixes with mannitol, lactose, L-arabinose and flavoring orange essence, aqueous povidone solution with 5% is as binder solution soft material, cross 20 mesh sieve granules, 55 DEG C of dryings 2 hours, 16 mesh sieve granulate are for subsequent use;
Step 3: the dried particles of step 2 gained adds micropowder silica gel mix homogeneously, tabletting.
Embodiment 2
Get the raw materials ready according to following prescription:
Herba Sarcandrae 3100g, mannitol 170g, lactose 150g, polyvinylpyrrolidone 10g, flavoring orange essence 6g, micropowder silica gel 3g.
Method for making:
Step one: get Herba Sarcandrae Herb, chopping, extracts, concentrated, and it is for subsequent use to dry, pulverize into Herba Sarcandrae extract; Wherein, the leaching process of Herba Sarcandrae is: Herba Sarcandrae coarse crushing, adds 10,8,8 times amount soak by water three times, 5 hours first times, and second time and each 1 hour of third time, decocting liquid filters, and filtrate merges, and is condensed into relative density 1.1 ~ 1.15g/cm
3thick paste, drying under reduced pressure becomes dry extract, pulverizes, and wherein, collect volatile oil in first time decoction process, the atomization of gained volatile oil evenly sprays in the dry extract after pulverizing, obtains Herba Sarcandrae extract;
Step 2: the Herba Sarcandrae extract of step one gained fully mixes with mannitol, lactose and flavoring orange essence, the aqueous povidone solution with 5%, as binder solution soft material, crosses 20 mesh sieve granules, 60 DEG C of dryings 1 hour, and 16 mesh sieve granulate are for subsequent use;
Step 3: the dried particles of step 2 gained adds micropowder silica gel mix homogeneously, tabletting.
Embodiment 3
Get the raw materials ready according to following prescription:
Herba Sarcandrae 3200g, lactose 150g, L-arabinose 170g, polyvinylpyrrolidone 10g, flavoring orange essence 6g, micropowder silica gel 3g.
Method for making:
Step one: get Herba Sarcandrae Herb, chopping, extracts, concentrated, and it is for subsequent use to dry, pulverize into Herba Sarcandrae extract; Wherein, the leaching process of Herba Sarcandrae is: Herba Sarcandrae coarse crushing, adds 10,8,8 times amount soak by water three times, 4 hours first times, second and third difference 2 hours, and decocting liquid filters, and filtrate merges, and is condensed into relative density 1.1 ~ 1.15g/cm
3thick paste, drying under reduced pressure becomes dry extract, pulverizes, and wherein, collect volatile oil in first time decoction process, the atomization of gained volatile oil evenly sprays in the dry extract after pulverizing, obtains Herba Sarcandrae extract;
Step 2: the Herba Sarcandrae extract of step one gained fully mixes with lactose, L-arabinose and flavoring orange essence, aqueous povidone solution with 5% is as binder solution soft material, cross 20 mesh sieve granules, 50 DEG C of dryings 1 hour, 16 mesh sieve granulate are for subsequent use;
Step 3: the dried particles of step 2 gained adds micropowder silica gel mix homogeneously, tabletting.
Embodiment 4 Herba Sarcandrae chewable tablet is to the rat auricle inflammation pharmacodynamic evaluation caused by LPS
1, trial drug: the embodiment of the present invention 1 Herba Sarcandrae chewable tablet, positive control drug is commercially available ZHONGJIEFENG PIAN.
2, experimental animal and grouping:
Experimental animal: 6 week age Wistar rat 60, adopt auricle injection LPS mono-week formation local inflammation focus.
Test grouping: be divided into basic, normal, high test group, positive controls, negative control group and blank group, often organize 10.The basic, normal, high dosage group of embodiment 1 Herba Sarcandrae chewable tablet (dosage is respectively 3,10,30mg Herba Sarcandrae extract/kg/d, 1g extract is equivalent to crude drug 13.5g), positive controls (10mg Herba Sarcandrae extract/kg/d, 1g extract is equivalent to crude drug 13.3g), negative control group gives blank, and blank group does not inject LPS and not administration.
3, test method: modeling started daily after a week, Herba Sarcandrae chewable tablet and ZHONGJIEFENG PIAN pulverize gavage, one month afterwards continuous observation animal situation record.
4, observation index:
1. body outward appearance, local redness are festered area; 2. TNF secretes concentration level; 3. rat serum routine monitoring; 4. rat motor posture, the mental status, feed inflow, body weight change etc.
5, evaluation criterion is in table 1:
Table 1 inflammation level evaluation standard
6, result of the test:
Naive animals body condition, feed, activity etc. are all normal, the low ripple disable of TNF value.
Be chosen as 3 grades during negative control group administration, after 5 days, be upgraded to 4 grades.
Be chosen as 3 grades during positive controls administration, after 11 days, reduce to 2 grades, after 18 days, reduce to 1 grade, after 23 days, reduce to 0 grade, total effective rate 87%.
Be chosen as 3 grades during the administration of low dosage test group, after 8 days, reduce to 2 grades, after 12 days, reduce to 1 grade, after 20 days, reduce to 0 grade, total effective rate 82%.
Be chosen as 3 grades during middle dosetest group administration, after 6 days, reduce to 2 grades, after 9 days, reduce to 1 grade, after 11 days, reduce to 0 grade, total effective rate 92%.
Be chosen as 3 grades during the administration of high dose test group, after 2 days, reduce to 2 grades, after 4 days, reduce to 1 grade, after 8 days, reduce to 0 grade, total effective rate 99%.
High, middle dosage group antiphlogistic effects is better than positive controls, has significant difference; Low dose group before administration two weeks antiphlogistic effects is obviously better than positive controls, has significant difference.
Embodiment 5 test-meal is tested
Stochastic choice 100 routine inflammatory patient takes embodiment 1 ~ 3 Herba Sarcandrae chewable tablet and commercially available ZHONGJIEFENG PIAN, mouthfeel is evaluated, 98% thinks that the Herba Sarcandrae chewable tablet of embodiment 1 ~ 3 is easily chewed easily swallows, mouthfeel is good, there are refrigerant sense and fruit sweet taste etc., be easier to accept compared with commercially available ZHONGJIEFENG PIAN dysphagia, wherein the mouthfeel of embodiment 1 ~ 3 compares, and embodiment 1 mouthfeel is best.
Embodiment 6 slaking test
According to inspection technique under Chinese Pharmacopoeia version in 2010 item disintegration, respectively get 6 to the chewable tablet of embodiment 1 ~ 3 to measure, each of result all passes through screen cloth in 15min, wherein 6 of embodiment 1 average is 8.5min by the screen cloth time, embodiment 2 is 12.2min, and embodiment 3 is 7.3min.
Above-described embodiment is only for illustrating technical conceive of the present invention and advantage; the present invention also can have other variation; as well known to the skilled person; above-described embodiment only plays the exemplary role in foregoing invention protection domain; for those of ordinary skills; in the protection domain that the present invention limits, also have a lot of conventional deformation and other embodiment, these distortion and embodiment are all by within the protection domain that awaits the reply in the present invention.
Claims (8)
1. a Herba Sarcandrae chewable tablet, it is characterized in that: be prepared from by the composition of following weight portion: Herba Sarcandrae 3000 ~ 3200 parts, filler 210 ~ 230 parts, binding agent 5 ~ 15 parts, correctives 4 ~ 8 parts, lubricant 1 ~ 5 part, wherein, described filler be selected from mannitol, lactose or L-arabinose one or more, described binding agent is polyvinylpyrrolidone, and described lubricant is micropowder silica gel.
2. Herba Sarcandrae chewable tablet as claimed in claim 1, is characterized in that: be prepared from by the composition of following weight portion: Herba Sarcandrae 3125 parts, filler 220 parts, binding agent 10 parts, correctives 6 parts, lubricant 3 parts.
3. Herba Sarcandrae chewable tablet as claimed in claim 1 or 2, is characterized in that: described filler is mannitol: lactose: L-arabinose weight ratio is the mixture of 9:7:6.
4. Herba Sarcandrae chewable tablet as claimed in claim 1 or 2, is characterized in that: described correctives is flavoring orange essence.
5. Herba Sarcandrae chewable tablet as claimed in claim 1 or 2, is characterized in that: be prepared from according to following preparation method:
Step one: get Herba Sarcandrae Herb, chopping, extracts, concentrated, and it is for subsequent use to dry, pulverize into Herba Sarcandrae extract;
Step 2: the Herba Sarcandrae extract of step one gained fully mixes with filler, correctives, the aqueous povidone solution with 5 ~ 10%, as binder solution soft material, crosses 20 mesh sieve granules, 50 ~ 60 DEG C of dryings 1 ~ 2 hour, and 16 order granulate are for subsequent use;
Step 3: the dried particles of step 2 gained adds mix lubricant evenly, and tabletting, to obtain final product.
6. Herba Sarcandrae chewable tablet as claimed in claim 5, it is characterized in that: in described preparation method, the concrete operation method of step one is: Herba Sarcandrae coarse crushing, add 10,8,8 times amount soak by water three times, 4 ~ 5 hours first times, be respectively 1 ~ 2 hour for the second time, for the third time, decocting liquid filters, filtrate merges, and is condensed into relative density 1.1-1.15g/cm
3thick paste, drying under reduced pressure becomes dry extract, pulverizes, and wherein, collect volatile oil in first time decoction process, the atomization of gained volatile oil evenly sprays in the dry extract after pulverizing, obtains Herba Sarcandrae extract.
7. the preparation method of Herba Sarcandrae chewable tablet as claimed in claim 1 or 2, is characterized in that: comprise the steps:
Step one: get Herba Sarcandrae Herb, chopping, extracts, concentrated, and it is for subsequent use to dry, pulverize into Herba Sarcandrae extract;
Step 2: the Herba Sarcandrae extract of step one gained fully mixes with filler and correctives, the aqueous povidone solution with 5%, as binder solution soft material, crosses 20 mesh sieve granules, 50 ~ 60 DEG C of dryings 1 ~ 2 hour, and 16 mesh sieve granulate are for subsequent use;
Step 3: the dried particles of step 2 gained adds mix lubricant evenly, tabletting.
8. the preparation method of Herba Sarcandrae chewable tablet as claimed in claim 7, it is characterized in that: the concrete operations of described step one are: Herba Sarcandrae coarse crushing, add 10,8,8 times amount soak by water three times, 4 ~ 5 hours first times, for the second time, third time is respectively 1 ~ 2 hour, decocting liquid filters, and filtrate merges, and is condensed into relative density 1.1-1.15g/cm
3thick paste, drying under reduced pressure becomes dry extract, pulverizes, and wherein, collect volatile oil in first time decoction process, the atomization of gained volatile oil evenly sprays in the dry extract after pulverizing, obtains Herba Sarcandrae extract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410763905.4A CN104523774B (en) | 2014-12-11 | 2014-12-11 | A kind of Glabrous Sarcandra Herb chewable tablets and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410763905.4A CN104523774B (en) | 2014-12-11 | 2014-12-11 | A kind of Glabrous Sarcandra Herb chewable tablets and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104523774A true CN104523774A (en) | 2015-04-22 |
| CN104523774B CN104523774B (en) | 2017-09-29 |
Family
ID=52839530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410763905.4A Active CN104523774B (en) | 2014-12-11 | 2014-12-11 | A kind of Glabrous Sarcandra Herb chewable tablets and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104523774B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1939358A (en) * | 2005-09-30 | 2007-04-04 | 江西本草天工科技有限责任公司 | Sarcandra glaber dispersant tablets |
| JP2008247854A (en) * | 2007-03-30 | 2008-10-16 | Shiseido Co Ltd | Antioxidant, dna damage suppressant, and external skin preparation |
| CN103705832A (en) * | 2013-12-27 | 2014-04-09 | 王恩芹 | Astragalus chewable tablets and preparation method thereof |
-
2014
- 2014-12-11 CN CN201410763905.4A patent/CN104523774B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1939358A (en) * | 2005-09-30 | 2007-04-04 | 江西本草天工科技有限责任公司 | Sarcandra glaber dispersant tablets |
| JP2008247854A (en) * | 2007-03-30 | 2008-10-16 | Shiseido Co Ltd | Antioxidant, dna damage suppressant, and external skin preparation |
| CN103705832A (en) * | 2013-12-27 | 2014-04-09 | 王恩芹 | Astragalus chewable tablets and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 李迪等: "肿节风含片制备工艺的研究", 《医药世界》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104523774B (en) | 2017-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103156095B (en) | Mixed feed of young broiler chickens and preparation method of feed | |
| CN103285176B (en) | Micro-powder granules for treating fever disease of pigs and preparation process thereof | |
| CN100345572C (en) | Medicine composition for curing exogenous fever and process for preparing the same | |
| CN106361830B (en) | Rhubarb powder and preparation method thereof | |
| CN101411417B (en) | Propolis chawing pieces and processing technique | |
| CN102048967A (en) | Inflammation-diminishing and heat-clearing composition and preparation method thereof | |
| CN104324120A (en) | Chinese herbal medicine compound preparation for treating pullorum disease | |
| CN111329966A (en) | Traditional Chinese medicine composition for treating skin itch and extract and preparation thereof | |
| CN104940781A (en) | Traditional Tibetan medicine composition for treating nervous system diseases and preparation method thereof | |
| CN102813850A (en) | Traditional Chinese medicine composition for preventing and treating poultry coccidiosis and preparation method of traditional Chinese medicine composition | |
| CN103191282B (en) | Traditional Chinese medicinal composition for treating fever in children as well as preparation method and application thereof | |
| CN106310138A (en) | Traditional Chinese medicine composition for preventing diarrhea of suckling pig and preparation method thereof | |
| CN101716300A (en) | Cough relief traditional Chinese medicine compound preparation and preparation method thereof | |
| CN102652819B (en) | Fuyankang dispersible tablet and preparation method thereof | |
| CN101199652B (en) | Medicine for treating acute and subacute eczema and preparation method thereof | |
| CN104523774A (en) | Sarcandra glabra chewable tablets and preparation method thereof | |
| CN100372555C (en) | Chinese medicinal granule for clearing pharynx and moistening throat and preparation method thereof | |
| CN108553584B (en) | A kind of composition for assisting hypoglycemic and its application | |
| CN100402073C (en) | Medicine for treating disease caused by heat toxin | |
| CN1709302A (en) | Chinese medicine formulation for treating chronic pelvic inflammation and its preparing method | |
| CN100444875C (en) | Common cold heat clearing chewing tablet and its preparation method | |
| CN102309628A (en) | Traditional Chinese medicinal particle for treating dog tonsillopathy and preparation method thereof | |
| CN1660332A (en) | Drop pills preparation of dual goldthread root and preparation method | |
| CN101543523A (en) | Uyghur drug compound recipe extracting technology for chiccory | |
| CN101239103A (en) | Clearing heat and detoxication traditional Chinese medicine preparation and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |